Literature DB >> 7958973

Triple-helices targeted to the polypurine tract of a murine retrovirus.

H Porumb1, C Dagneaux, R Letellier, C Malvy, E Taillandier.   

Abstract

The all-purine 13-mer oligodeoxyribonucleotide d(GGGGGGAAAAAGA), containing an unusually large block of contiguous guanines, was shown by electrophoresis and thermoelution to form a specific, 'antiparallel' complex with the duplex containing the polypurine tract of murine retroviruses. Fourier transform infra-red spectroscopy (FTIR) and molecular modeling indicated that the complex is based on reverse Hoogsteen G(GC) and A(AT) triplets, with anti orientations of the bases and with all the strands having S-type sugar conformations. This G + A-containing 13-mer and a G + T-containing 22-mer, d(TGTTTGTTTGGGGGGTTTTTGT), aimed at the same target, retarded in a sequence-specific manner the spreading of the Friend retrovirus in Dunni cells infected de novo, thus indicating that the polypurine tract of retroviruses may be a suitable target for anti-gene action.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7958973     DOI: 10.1016/0378-1119(94)90417-0

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  3 in total

1.  Parallel and antiparallel A*A-T intramolecular triple helices.

Authors:  C Dagneaux; H Gousset; A K Shchyolkina; M Ouali; R Letellier; J Liquier; V L Florentiev; E Taillandier
Journal:  Nucleic Acids Res       Date:  1996-11-15       Impact factor: 16.971

2.  The high stability of the triple helices formed between short purine oligonucleotides and SIV/HIV-2 vpx genes is determined by the targeted DNA structure.

Authors:  F Svinarchuk; M Monnot; A Merle; C Malvy; S Fermandjian
Journal:  Nucleic Acids Res       Date:  1995-10-11       Impact factor: 16.971

3.  Triplex formation by a psoralen-conjugated oligodeoxyribonucleotide containing the base analog 8-oxo-adenine.

Authors:  P S Miller; G Bi; S A Kipp; V Fok; R K DeLong
Journal:  Nucleic Acids Res       Date:  1996-02-15       Impact factor: 16.971

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.